109 related articles for article (PubMed ID: 21432982)
1. Renal involvement and left ventricular hypertrophy are novel risk factors for morbidity and mortality in diabetes mellitus.
Boner G
Diabetes Metab Res Rev; 2011 Jul; 27(5):425-9. PubMed ID: 21432982
[TBL] [Abstract][Full Text] [Related]
2. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population.
Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Giannattasio C; Grassi G; Sega R
J Hypertens; 2008 Aug; 26(8):1602-11. PubMed ID: 18622239
[TBL] [Abstract][Full Text] [Related]
3. The need for tighter control of cardiovascular risk factors in diabetic patients.
Viberti G
J Hypertens Suppl; 2003 Mar; 21(1):S3-6. PubMed ID: 12769160
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular hypertrophy in hypertensive type 2 diabetic patients according to renal function.
Blanchet Deverly A; Kangambega P; Hue K; Donnet JP; Merault H; Foucan L
Diabetes Metab; 2009 Sep; 35(4):280-6. PubMed ID: 19423378
[TBL] [Abstract][Full Text] [Related]
5. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
Minami J; Ishimitsu T; Sudo Y; Matsuoka H
Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
[TBL] [Abstract][Full Text] [Related]
6. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk.
Liefeldt L; Budde K
Transpl Int; 2010 Dec; 23(12):1191-204. PubMed ID: 21059108
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.
Gerstein HC; Mann JF; Pogue J; Dinneen SF; Hallé JP; Hoogwerf B; Joyce C; Rashkow A; Young J; Zinman B; Yusuf S
Diabetes Care; 2000 Apr; 23 Suppl 2():B35-9. PubMed ID: 10860189
[TBL] [Abstract][Full Text] [Related]
9. [Left ventricular hypertrophy in the Spanish hypertensive population. The ERIC-HTA study].
Lozano JV; Redón J; Cea-Calvo L; Fernández-Pérez C; Navarro J; Bonet A; González-Esteban J
Rev Esp Cardiol; 2006 Feb; 59(2):136-42. PubMed ID: 16540035
[TBL] [Abstract][Full Text] [Related]
10. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular morbidity and mortality in thyroid dysfunction.
Dörr M; Völzke H
Minerva Endocrinol; 2005 Dec; 30(4):199-216. PubMed ID: 16319809
[TBL] [Abstract][Full Text] [Related]
12. [Ventricular arrhythmia and sudden cardiac death: the significance of left ventricular hypertrophy as risk factor].
Schmieder RE; Messerli FH
Schweiz Med Wochenschr; 1993 Jan; 123(4):99-107. PubMed ID: 7678943
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
14. [Cardiac failure in hypertensive cardiopathy].
Verdecchia P
Ital Heart J; 2000 Jun; 1 Suppl 2():72-7. PubMed ID: 10905132
[TBL] [Abstract][Full Text] [Related]
15. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
16. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
17. [Associations between arterial hypertension and other cardiovascular risk factors in subjects over 65 years of age].
Fiandra U; Bo M; Fonte G; Casoli G; Ferrario E
Recenti Prog Med; 1995 Apr; 86(4):147-54. PubMed ID: 7617957
[TBL] [Abstract][Full Text] [Related]
18. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
[TBL] [Abstract][Full Text] [Related]
19. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
[TBL] [Abstract][Full Text] [Related]
20. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
